Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Gains from Sales and Divestitures (2025)

NewAmsterdam Pharma's Gains from Sales and Divestitures history spans 1 years, with the latest figure at $143001.0 for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures changed N/A year-over-year to $143001.0; the TTM value through Dec 2025 reached $143001.0, changed N/A, while the annual FY2025 figure was $143001.0, N/A changed from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $143001.0 at NewAmsterdam Pharma, roughly flat from $143001.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $143001.0 in Q2 2025 and bottomed at $142795.0 in Q1 2025.